Back to Journals » Therapeutics and Clinical Risk Management » Volume 7

Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor

Total article views   Abstract views HTML views PDF downloads Totals
11,978 Dovepress* 9,275 649+ 2,236 9,924
PubMed Central* 9 2,045 536 2,054
Totals 9,284 2,694 2,772 11,978
*Since 9 August 2011
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
2 0 0 0 0 2

View citations on PubMed Central and Google Scholar